Toru Shimazui

Kasama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.

Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.

Journal: International journal of clinical oncology

Published: September 17, 2024

Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.

Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.

Journal: Urologic oncology

Published: January 27, 2023

Abdominal nonfunctional paraganglioma in which succinate dehydrogenase subunit B (SDHB) immunostaining was performed: a case report.

Abdominal nonfunctional paraganglioma in which succinate dehydrogenase subunit B (SDHB) immunostaining was performed: a case report.

Journal: Journal of medical case reports

Published: December 08, 2022

ELOVL5-mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma.

ELOVL5-mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma.

Journal: Cancer science

Published: March 11, 2022

Renal Mucinous Tubular and Spindle Cell Carcinoma : A Case Report

Renal Mucinous Tubular and Spindle Cell Carcinoma : A Case Report

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: July 16, 2021

ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.

ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.

Journal: Oncology reports

Published: May 27, 2021

Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.

Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.

Journal: Journal of geriatric oncology

Published: April 27, 2021

Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.

Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.

Journal: Cancer science

Published: April 16, 2021

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.

Journal: Cancer immunology, immunotherapy : CII

Published: January 08, 2021

Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma.

Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma.

Journal: Journal of geriatric oncology

Published: October 02, 2020

Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.

Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.

Journal: Cancer science

Published: September 28, 2020

Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer.

Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer.

Journal: BJUI compass

Published: May 07, 2020

Showing 1-12 of 37

Last Updated: 09/26/2026